2026 Q2 - tulosraportti
49 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 985 | - | - | ||
| 5 000 | - | - | ||
| 162 | - | - | ||
| 2 063 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sitten1 week left to wait....exciting ὠ6 Usually you want time to go slowly, but now I hope time fliesὠ5- ·11 t sitten · MuokattuNew acquisition in the RNA segment today. Merck is acquiring Silence Therapeutics for 1.3 billion dollars.
·11 t sittenCIRCIO AND CAR-M – SCIENTIFIC DEEP DIVE (PART 1/5) Why macrophages could become a new type of cell therapy CAR-T has given impressive results in several blood cancers, but treatment of solid tumors is more difficult. The tumor tissue can be dense, immunosuppressive and difficult for T cells to penetrate. Therefore, CAR-macrophages (CAR-M) are also being investigated. WHAT IS A MACROPHAGE? Macrophages belong to the innate immune system. They can take up and break down foreign particles, dead cells and other material through phagocytosis. They also contribute to signaling, antigen presentation, inflammation and tissue repair. Many solid tumors contain large amounts of tumor-associated macrophages (TAM). The problem is that the tumor can influence these cells to support cancer growth or inhibit other immune cells. Macrophages are plastic: their function depends on signals in the environment. The usual division into M1 and M2 is therefore a simplification, not two fixed cell types. WHAT DOES A CAR-M DO? A chimeric antigen receptor (CAR) can enable the macrophage to recognize a specific target. The goal is for it to be able to: • Recognize and phagocytose target cells. • Activate inflammatory and immune signals locally. • Present antigens and help activate T cells. • Counteract an immunosuppressive tumor microenvironment. This means that a CAR-M in theory can do more than attack the cancer cell directly: It can also affect the environment around the tumor. But such effects vary with CAR design, target protein, cell type and disease model. Klichinsky and colleagues showed in Nature Biotechnology in 2020 that genetically altered human CAR-macrophages could phagocytose targeted cancer cells. In mouse models with solid tumors, tumor burden was reduced and survival improved. The experiments also showed effects on other immune cells and the tumor environment. These were important preclinical proofs for CAR-M as a treatment principle. They were not experiments with circVec. EX VIVO VS IN VIVO Traditional CAR-M is produced by harvesting cells from the patient, gene-modifying them in a laboratory and infusing them back. This requires individual cell production. In in vivo CAR-M, one instead tries to program macrophages directly in the body with a delivery system that carries in genetic instructions. If it works, the treatment could become easier to produce and administer. However, it is not proven that this method will be clinically cheaper or more effective. This is where Circio comes in: The company aims to combine its DNA-based circVec cassette with a technology that can deliver it to the right myeloid cells. The scientific idea is interesting, but must not be confused with already documented CAR-M efficacy in animals or patients. There is still no public documentation of functioning circVec-based CAR-M. Sources and studies are compiled in part 5.
Isn't it rather pretentious to call this AI driving a scientific deep dive? SITC the presentation does not pretend to be anything other than results (good ones) of a delivery technology P-LNP. It is known that Circio tests various LNP delivery technologies. UI-102 is another project and a separate study not placed under the CAR-M project at UI. There, an agreement with Roche has recently been announced in their project a combination with an immune inhibitor.- ·15 t sitten · MuokattuFor 7 months ago Circio entered into an agreement with Japanese United Immunity. The collaboration was to test P-LNP delivery technology targeting myeloid cells, such as macrophages and dendritic cells. P-LNP P-LNP is designed to selectively deliver RNA- and DNA-based therapeutics to macrophages and dendritic cells. Unlike conventional LNPs, P-LNP replaces polyethylene glycol (PEG)-lipids with CHP, reducing concerns associated with anti-PEG antibodies and the accelerated blood clearance (ABC) effect. This allows for multiple repeated dosing with P-LNP. P-LNP is useful to engineer macrophages and dendritic cells using RNA or DNA in vivo. In vivo CAR-M. Now United I is coming with a presentation of P-LNP. See attachment13 t sittenin vivo CAR-M, a novel therapeutic approach against cancer, fibrosis, and autoimmune disorders
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
49 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sitten1 week left to wait....exciting ὠ6 Usually you want time to go slowly, but now I hope time fliesὠ5
- ·11 t sitten · MuokattuNew acquisition in the RNA segment today. Merck is acquiring Silence Therapeutics for 1.3 billion dollars.
- ·11 t sittenCIRCIO AND CAR-M – SCIENTIFIC DEEP DIVE (PART 1/5) Why macrophages could become a new type of cell therapy CAR-T has given impressive results in several blood cancers, but treatment of solid tumors is more difficult. The tumor tissue can be dense, immunosuppressive and difficult for T cells to penetrate. Therefore, CAR-macrophages (CAR-M) are also being investigated. WHAT IS A MACROPHAGE? Macrophages belong to the innate immune system. They can take up and break down foreign particles, dead cells and other material through phagocytosis. They also contribute to signaling, antigen presentation, inflammation and tissue repair. Many solid tumors contain large amounts of tumor-associated macrophages (TAM). The problem is that the tumor can influence these cells to support cancer growth or inhibit other immune cells. Macrophages are plastic: their function depends on signals in the environment. The usual division into M1 and M2 is therefore a simplification, not two fixed cell types. WHAT DOES A CAR-M DO? A chimeric antigen receptor (CAR) can enable the macrophage to recognize a specific target. The goal is for it to be able to: • Recognize and phagocytose target cells. • Activate inflammatory and immune signals locally. • Present antigens and help activate T cells. • Counteract an immunosuppressive tumor microenvironment. This means that a CAR-M in theory can do more than attack the cancer cell directly: It can also affect the environment around the tumor. But such effects vary with CAR design, target protein, cell type and disease model. Klichinsky and colleagues showed in Nature Biotechnology in 2020 that genetically altered human CAR-macrophages could phagocytose targeted cancer cells. In mouse models with solid tumors, tumor burden was reduced and survival improved. The experiments also showed effects on other immune cells and the tumor environment. These were important preclinical proofs for CAR-M as a treatment principle. They were not experiments with circVec. EX VIVO VS IN VIVO Traditional CAR-M is produced by harvesting cells from the patient, gene-modifying them in a laboratory and infusing them back. This requires individual cell production. In in vivo CAR-M, one instead tries to program macrophages directly in the body with a delivery system that carries in genetic instructions. If it works, the treatment could become easier to produce and administer. However, it is not proven that this method will be clinically cheaper or more effective. This is where Circio comes in: The company aims to combine its DNA-based circVec cassette with a technology that can deliver it to the right myeloid cells. The scientific idea is interesting, but must not be confused with already documented CAR-M efficacy in animals or patients. There is still no public documentation of functioning circVec-based CAR-M. Sources and studies are compiled in part 5.Isn't it rather pretentious to call this AI driving a scientific deep dive? SITC the presentation does not pretend to be anything other than results (good ones) of a delivery technology P-LNP. It is known that Circio tests various LNP delivery technologies. UI-102 is another project and a separate study not placed under the CAR-M project at UI. There, an agreement with Roche has recently been announced in their project a combination with an immune inhibitor.
- ·15 t sitten · MuokattuFor 7 months ago Circio entered into an agreement with Japanese United Immunity. The collaboration was to test P-LNP delivery technology targeting myeloid cells, such as macrophages and dendritic cells. P-LNP P-LNP is designed to selectively deliver RNA- and DNA-based therapeutics to macrophages and dendritic cells. Unlike conventional LNPs, P-LNP replaces polyethylene glycol (PEG)-lipids with CHP, reducing concerns associated with anti-PEG antibodies and the accelerated blood clearance (ABC) effect. This allows for multiple repeated dosing with P-LNP. P-LNP is useful to engineer macrophages and dendritic cells using RNA or DNA in vivo. In vivo CAR-M. Now United I is coming with a presentation of P-LNP. See attachment13 t sittenin vivo CAR-M, a novel therapeutic approach against cancer, fibrosis, and autoimmune disorders
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 985 | - | - | ||
| 5 000 | - | - | ||
| 162 | - | - | ||
| 2 063 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
49 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sitten1 week left to wait....exciting ὠ6 Usually you want time to go slowly, but now I hope time fliesὠ5
- ·11 t sitten · MuokattuNew acquisition in the RNA segment today. Merck is acquiring Silence Therapeutics for 1.3 billion dollars.
- ·11 t sittenCIRCIO AND CAR-M – SCIENTIFIC DEEP DIVE (PART 1/5) Why macrophages could become a new type of cell therapy CAR-T has given impressive results in several blood cancers, but treatment of solid tumors is more difficult. The tumor tissue can be dense, immunosuppressive and difficult for T cells to penetrate. Therefore, CAR-macrophages (CAR-M) are also being investigated. WHAT IS A MACROPHAGE? Macrophages belong to the innate immune system. They can take up and break down foreign particles, dead cells and other material through phagocytosis. They also contribute to signaling, antigen presentation, inflammation and tissue repair. Many solid tumors contain large amounts of tumor-associated macrophages (TAM). The problem is that the tumor can influence these cells to support cancer growth or inhibit other immune cells. Macrophages are plastic: their function depends on signals in the environment. The usual division into M1 and M2 is therefore a simplification, not two fixed cell types. WHAT DOES A CAR-M DO? A chimeric antigen receptor (CAR) can enable the macrophage to recognize a specific target. The goal is for it to be able to: • Recognize and phagocytose target cells. • Activate inflammatory and immune signals locally. • Present antigens and help activate T cells. • Counteract an immunosuppressive tumor microenvironment. This means that a CAR-M in theory can do more than attack the cancer cell directly: It can also affect the environment around the tumor. But such effects vary with CAR design, target protein, cell type and disease model. Klichinsky and colleagues showed in Nature Biotechnology in 2020 that genetically altered human CAR-macrophages could phagocytose targeted cancer cells. In mouse models with solid tumors, tumor burden was reduced and survival improved. The experiments also showed effects on other immune cells and the tumor environment. These were important preclinical proofs for CAR-M as a treatment principle. They were not experiments with circVec. EX VIVO VS IN VIVO Traditional CAR-M is produced by harvesting cells from the patient, gene-modifying them in a laboratory and infusing them back. This requires individual cell production. In in vivo CAR-M, one instead tries to program macrophages directly in the body with a delivery system that carries in genetic instructions. If it works, the treatment could become easier to produce and administer. However, it is not proven that this method will be clinically cheaper or more effective. This is where Circio comes in: The company aims to combine its DNA-based circVec cassette with a technology that can deliver it to the right myeloid cells. The scientific idea is interesting, but must not be confused with already documented CAR-M efficacy in animals or patients. There is still no public documentation of functioning circVec-based CAR-M. Sources and studies are compiled in part 5.Isn't it rather pretentious to call this AI driving a scientific deep dive? SITC the presentation does not pretend to be anything other than results (good ones) of a delivery technology P-LNP. It is known that Circio tests various LNP delivery technologies. UI-102 is another project and a separate study not placed under the CAR-M project at UI. There, an agreement with Roche has recently been announced in their project a combination with an immune inhibitor.
- ·15 t sitten · MuokattuFor 7 months ago Circio entered into an agreement with Japanese United Immunity. The collaboration was to test P-LNP delivery technology targeting myeloid cells, such as macrophages and dendritic cells. P-LNP P-LNP is designed to selectively deliver RNA- and DNA-based therapeutics to macrophages and dendritic cells. Unlike conventional LNPs, P-LNP replaces polyethylene glycol (PEG)-lipids with CHP, reducing concerns associated with anti-PEG antibodies and the accelerated blood clearance (ABC) effect. This allows for multiple repeated dosing with P-LNP. P-LNP is useful to engineer macrophages and dendritic cells using RNA or DNA in vivo. In vivo CAR-M. Now United I is coming with a presentation of P-LNP. See attachment13 t sittenin vivo CAR-M, a novel therapeutic approach against cancer, fibrosis, and autoimmune disorders
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 985 | - | - | ||
| 5 000 | - | - | ||
| 162 | - | - | ||
| 2 063 | - | - | ||
| 1 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt